Spyre Therapeutics, Inc. SYRE R2K

Healthcare · Biotechnology · United States

https://www.spyre.com

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Market & Price

Market Cap

$6.38B

Current Price

$73.50

High / Low (52W)

$76.43 / $14.68

Beta

3.13

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$6.53

Price to Book

11.25

P/S

EV/EBITDA

Dividend Yield

Profitability & Returns

ROCE

-30.53%

ROE

-31.11%

ROA

-22.65%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.74

EPS (TTM)

$-2.12

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

8.80

Current Ratio

8.97

Debt

Total Assets

$777.78M

Current Assets

$777.78M

Working Capital

$719.10M

Ownership

Promoter Holding

5.90%

Chg in Prom Hold

FII / Inst Holding

97.87%

Chg in FII Hold

0.35%

Financial Snapshot

Enterprise Value

$5.80B

Total Revenue (TTM)

EBITDA

Free Cash Flow

$-75.52M

Operating Cash Flow

$-185.63M

Shares Outstanding

86.84M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-33.33%

Profit 5Y

-72.04%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -33.3% CAGR over 5 years.
Earnings shrank at -72.0% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SYRE Spyre Therapeutics, Inc. R2K	73.50	-	$6.38B	-	-30.53%	-31.11%	-33.33%	-72.04%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	982.00K	1.48M	1.26M	1.48M	1.51M	2.38M	0	0	0	-	-	-	-	-	-	-	0	13.70M	1.40M	1.36M	625.00K	174.00K	198.00K	688.00K	0	0	0	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53.57M	51.94M	56.89M	57.17M	75.64M
Operating Income	-3.42M	-4.00M	-4.57M	-5.50M	-6.30M	-5.54M	-6.33M	-6.72M	-8.00M	-6.63M	-8.24M	-9.67M	-12.24M	-15.30M	-17.66M	-18.62M	-22.15M	-21.91M	-19.02M	-21.56M	-18.12M	-22.78M	-18.21M	-6.71M	-20.29M	-24.44M	-22.42M	-18.75M	-18.81M	-159.25M	-18.34M	-47.77M	-44.15M	-	-	-53.57M	-51.94M	-56.89M	-57.17M	-75.64M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-53.57M	-51.94M	-56.89M	-57.17M	-75.64M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-44.79M	-36.72M	-11.18M	-62.53M	-69.00M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15.00K	0	0	0	0
Net Income	-3.41M	-3.99M	-4.55M	-5.43M	-6.24M	-5.48M	-6.25M	-6.63M	-7.87M	-6.48M	-8.12M	-9.41M	-11.92M	-14.90M	-17.17M	-18.02M	-21.57M	-21.50M	-18.73M	-21.42M	-18.03M	-22.71M	-18.22M	-6.83M	-20.31M	-24.44M	-22.32M	-18.23M	-18.42M	-217.08M	-40.11M	-43.86M	-38.84M	-	-	-44.77M	-36.72M	-11.18M	-62.53M	-69.00M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.10	-0.31	-0.37	-0.27	-4.84	-4.89	-56.79	-9.34	-1.20	-0.86	-	-	-0.60	-0.60	-0.18	-0.70	-0.74
R&D Expense	3.13M	-	3.60M	4.42M	5.38M	-	4.95M	5.83M	6.24M	-	6.87M	9.12M	8.93M	-	14.39M	14.81M	17.84M	-	14.56M	16.87M	12.45M	-	11.86M	13.58M	14.85M	16.98M	15.37M	11.98M	13.78M	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	4.63M	5.21M	3.89M	0	0	-	2.33M	886.00K	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	87.11M	129.45M	208.57M	219.56M
Operating Income	-8.90M	-11.31M	-21.91M	-27.68M	-45.46M	-80.33M	-81.48M	-	-84.78M	-128.56M	-208.57M	-219.56M
EBITDA	-	-	-	-	-	-	-	-	-82.82M	-127.82M	-208.57M	-219.56M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-83.95M	-338.82M	-207.97M	-155.22M
Tax Provision	-	-	-	-	-	-	-	-	-136.00K	-26.00K	51.00K	-15.00K
Net Income	-10.35M	-11.29M	-21.70M	-27.24M	-44.35M	-78.25M	-80.89M	-65.80M	-83.81M	-338.79M	-208.02M	-
Diluted EPS	-	-	-	-	-	-	-1.52	-	-24.75	-13.76	-3.18	-1.98
R&D Expense	6.83M	11.45M	18.14M	22.82M	36.72M	64.60M	59.64M	57.07M	58.58M	-	-	-

Compounded Sales Growth

5 Years:	-33.33%
1 Year:	-

Compounded Profit Growth

5 Years:	-72.04%
1 Year:	-

Stock Price Performance

1 Year:	+381.02%
6 Months:	+151.71%
3 Months:	+70.89%
1 Month:	+2.24%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	38.65M	67.06M	56.08M	77.74M	83.18M	161.62M	-	71.14M	341.86M	608.48M	777.78M
Current Assets	-	-	-	-	-	-	-	-	-	62.26M	341.53M	608.47M	777.78M
Cash & Equivalents	4.60M	2.62M	29.29M	47.75M	12.82M	22.46M	19.25M	90.09M	-	34.86M	188.89M	89.42M	85.72M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	815.00K	375.00K	0	-	-
Total Liabilities	-	-	2.55M	4.10M	5.74M	10.31M	23.10M	21.79M	-	20.84M	157.84M	90.68M	62.55M
Current Liabilities	-	-	2.52M	3.96M	5.63M	10.24M	18.36M	16.44M	-	14.66M	31.98M	54.06M	58.69M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	5.06M	4.63M	0	-	-
Total Equity	-1.27M	-11.47M	-22.21M	62.97M	50.34M	67.43M	60.08M	139.83M	-	50.30M	184.02M	517.80M	715.24M
Shares Outstanding	-	-	-	-	-	-	-	-	-	2.61M	36.06M	60.26M	78.19M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-18.84M	-24.61M	-32.19M	-65.69M	-75.78M	-	-80.14M	-99.91M	-157.41M	-169.25M
Investing Cash Flow	-	-	-12.08M	-22.53M	-15.23M	-1.74M	-7.60M	-	57.01M	-108.39M	-353.29M	-143.47M
Financing Cash Flow	-	-	49.37M	12.21M	57.07M	65.72M	154.51M	-	42.68M	361.08M	410.91M	309.02M
Capital Expenditure	-181.00K	-208.00K	-212.00K	-619.00K	-422.00K	-1.49M	-4.28M	-573.00K	-38.00K	-	-	-
Free Cash Flow	-	-	-19.05M	-25.23M	-32.62M	-67.18M	-80.06M	-	-80.18M	-99.91M	-157.41M	-169.25M
Net Change in Cash	-	-	-	-	-	-	-	-	19.54M	152.77M	-99.79M	-3.70M

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-473.3%	-531.7%	-1,169.3%	-	-	-	-3,640.2%	-14,510.6%	-	-
Net Margin %	-	-	-468.8%	-523.3%	-1,140.6%	-	-	-	-3,598.8%	-38,238.1%	-	-
ROE %	90.2%	50.9%	-34.5%	-54.1%	-65.8%	-130.2%	-57.9%	-	-166.6%	-184.1%	-40.2%	-
ROCE %	-	-31.3%	-34.7%	-54.9%	-67.4%	-123.9%	-56.1%	-	-150.1%	-41.5%	-37.6%	-30.5%

Shareholding Pattern

Insiders

5.90%

Institutions

97.87%

Public Float

104.01%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	13.57%	11.78M	$865.91M
2	Blackrock Inc.	6.36%	5.52M	$405.81M
3	RTW Investments LP	4.80%	4.17M	$306.64M
4	Fairmount Funds Management LLC	4.63%	4.02M	$295.33M
5	Perceptive Advisors Llc	4.36%	3.78M	$278.07M
6	Venrock Adviser, LLC	4.24%	3.69M	$270.88M
7	Vanguard Capital Management LLC	3.52%	3.06M	$224.72M
8	Driehaus Capital Management, LLC	3.21%	2.79M	$205.12M
9	State Street Corporation	3.00%	2.61M	$191.62M
10	Paradigm Biocapital Advisors LP	2.25%	1.96M	$143.86M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SYRE

No recent headlines available.

SYRE · Healthcare